Evolus launched its Evolysse Form and Evolysse Smooth injectable HA gels on April 18, following a national webcast and early access program involving over 1,000 aesthetic practices.
Evolus officially launched Evolysse Form and Evolysse Smooth, the first two products in its new collection of injectable hyaluronic acid (HA) gels, on April 18. The commercial debut marks the company’s expansion beyond its neurotoxin product Jeuveau, introduced in 2019.
National Webcast and Early Experience Program
To support the launch, Evolus hosted a national webcast through the Evolus Academy on April 18, drawing several thousand healthcare practitioners. Leading up to the launch, the company initiated an early experience program that provided product to over 1,000 aesthetic practices, including clinical investigators and key opinion leaders.
Clinical Use and Performance Data
Evolysse Form and Evolysse Smooth are designed for the treatment of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds. The products use Cold-X technology developed by Symatese, which is intended to preserve the natural structure of the HA molecule for long-lasting, natural-looking results.
In a clinical study comparing Evolysse products to Restylane-L, both Form and Smooth met the 6-month primary endpoint of non-inferiority, with statistical superiority shown, according to the company. Evolysse Form demonstrated significant differences at all timepoints during the 12-month study, while Evolysse Smooth showed statistically significant results at 6 and 9 months, despite 20% more Restylane-L being used. Both products demonstrated a similar safety profile to the control.
Industry Feedback
“With the introduction of Evolysse, we are bringing together the fastest growing toxin in the category with the first new innovation in HA technology in over a decade,” said David Moatazedi, president and CEO of Evolus. “This is more than a product launch, it is the introduction of differentiated injectable HA gels that are grounded in clinical science and designed to meet the evolving needs of consumers seeking natural-looking results.”
John Fezza, MD, an oculofacial plastic surgeon, commented, “With over 30 years of experience in the aesthetics industry, I’m excited to integrate Evolysse into my practice. These products represent the next generation of injectable HA gels, scientifically driven, delivering natural-looking results, and backed by a strong safety profile.”
Market Integration and Next Steps
Evolysse launches into an established customer network of more than 15,000 accounts built through Jeuveau, according to the company. With Jeuveau now present in over 50% of aesthetic clinics and holding more than 14% of the U.S. market, Evolus anticipates strong initial uptake of its new HA gel line across aesthetic practices nationwide.
Photo: ID 203920642 © Megaflopp | Dreamstime.com
